Loading...
•
Mar 31, 2020
McKesson Q4 2020 Earnings Report
McKesson delivered strong Q4 2020 results, driven by revenue growth and strategic transformation.
Key Takeaways
McKesson reported a 12% increase in fourth-quarter revenues to $58.5 billion and an adjusted EPS of $4.27, a 16% increase year-over-year. The results reflect continued momentum and progress in McKesson's transformation towards becoming a more focused organization. The company generated $3.9 billion of free cash flow and successfully completed the exit of its investment in Change Healthcare.
Total revenues increased by 12% to $58.5 billion.
Earnings per diluted share increased to $5.82.
Adjusted Earnings per diluted share increased by 16% to $4.27.
McKesson completed the separation of its investment in Change Healthcare.
McKesson
McKesson
McKesson Revenue by Segment
Revenue by Segment
U.S. Pharmaceutical Revenue
CapyFin.comMedical-Surgical Solutions Revenue
CapyFin.comInternational Revenue
CapyFin.com Forward Guidance
McKesson expects full-year fiscal 2021 Adjusted Earnings per diluted share of $13.95 to $14.75, which reflects anticipated headwinds in fiscal 2021 as a result of the COVID-19 pandemic and a continuation of disciplined, efficient capital deployment, including investments in the business. McKesson expects Adjusted Earnings per diluted share growth in the second half of fiscal 2021.
Revenue & Expenses
Visualization of income flow from segment revenue to net income